-
Mashup Score: 27
Bone Marrow Transplantation – Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study - 1 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation - 2 month(s) ago
Key Points. Young adults (18-25 years) are a distinct population with high rates of VOD.Disease-related factors predict for VOD in young adults (18-25 years) an
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 73
Extending the duration of letermovir prophylaxis to 200 days following HSCT is efficacious and safe in reducing the incidence of late clinically significant cytomegalovirus infection in patients at risk.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 68
Extending the duration of letermovir prophylaxis to 200 days following HSCT is efficacious and safe in reducing the incidence of late clinically significant cytomegalovirus infection in patients at risk.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Real‐world analysis of safety and efficacy of CAR T‐cell therapy in lymphoma patients with decreased kidney function - 5 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 5 month(s) ago
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with cancer and COVID-19.
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Probiotic-guided CAR-T cells for solid tumor targeting - 6 month(s) ago
Engineered probiotics produce synthetic targets to facilitate immunotherapy of solid tumors by CAR T cells.
Source: www.science.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma - 6 month(s) ago
Chimeric antigen receptor T cell (CAR-T) therapy has been applied in the treatment of B-cell lymphoma; however, CAR-T manufacturing requires virus- or non-virus-based genetic modification, which causes high manufacturing costs and potential safety concerns. Antibody–cell conjugation (ACC) technology, which originated from bio-orthogonal click chemistry, provides an efficient approach for arming immune cells with cancer-targeting antibodies without genetic modification. Here, we applied ACC technology in Vγ9Vδ2 T (γδ2 T) cells to generate a novel off-the-shelf CD20-targeting cell therapy ACE1831 (rituximab-conjugated γδ2 T cells) against relapsed/refractory B-cell lymphoma. ACE1831 exhibited superior cytotoxicity against B-cell lymphoma cells and rituximab-resistant cells compared to γδ2 T cells without rituximab conjugation. The in vivo xenograft study demonstrated that ACE1831 treatment strongly suppressed the aggressive proliferation of B-cell lymphoma and prolonged the survival of t
Source: www.mdpi.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Outcomes of toxoplasmosis after alloHCT. Antimicrobial prophylaxis improves PFS and OS in seropositive patients #bmtsm @AlexandreMALEK @Taha_CancerDoc @sairah__ahmed @MDAndersonNews https://t.co/ivHYl444pQ